Work Smart Witk Safe Work Again Jj White
Obes Sci Pract. 2021 Apr; 7(2): 137–147.
Torso mass alphabetize and risk of obesity‐related conditions in a cohort of 2.9 million people: Evidence from a UK primary care database
Christiane L. Haase
i Novo Nordisk A/S, Søborg Denmark,
Kirsten T. Eriksen
one Novo Nordisk A/S, Søborg Denmark,
Sandra Lopes
one Novo Nordisk A/S, Søborg Denmark,
Altynai Satylganova
1 Novo Nordisk A/Due south, Søborg Denmark,
Volker Schnecke
1 Novo Nordisk A/S, Søborg Denmark,
Phil McEwan
2 Wellness Economics and Outcomes Enquiry Ltd, Cardiff UK,
Received 2020 Jun 3; Revised 2020 Nov 12; Accepted 2020 Nov 28.
Abstract
Objective
Obesity rates in the Britain are some of the highest in Western Europe, with considerable clinical and societal impacts. Obesity is associated with type 2 diabetes (T2D), osteoarthritis, cardiovascular disease, and increased mortality; still, relatively few studies have examined the occurrence of multiple obesity‐related outcomes in the same patient population. This study was designed to examine the associations between body mass alphabetize (BMI) and a wide range of obesity‐related conditions in the same large cohort from a United kingdom‐representative primary intendance database.
Methods
Demographic information and diagnosis codes were extracted from the Clinical Exercise Research Datalink Gilt database in January 2019. Adults registered for ≥ 3 years were grouped by BMI, with BMI 18.5–24.9 kg/m2 as reference group. Associations betwixt BMI and 12 obesity‐related outcomes were estimated using Cox proportional adventure models, adapted for age, sex activity, and smoking.
Results
More than 2.9 one thousand thousand individuals were included in the analyses and were followed up for occurrence of relevant outcomes for a median of eleven.4 years during the report catamenia. By and large, there was a stepwise increase in risk of all outcomes with higher BMI. Individuals with BMI xl.0–45.0 kg/mii were at peculiarly high risk of slumber apnea (hazard ratio [95% confidence interval] vs. reference group: 19.8 [18.9–twenty.8]), T2D (12.four [12.1–12.seven]), heart failure (3.46 [3.35–3.57]), and hypertension (3.21 [iii.fifteen–3.26]).
Conclusions
This study substantiates evidence linking higher BMI to higher risk of a range of serious health conditions, in a big, representative UK cohort. By focusing on obesity‐related conditions, this demonstrates the wider clinical bear upon and the healthcare brunt of obesity, and highlights the vital importance of direction, handling approaches, and public wellness programs to mitigate the impact of this disease.
Keywords: body mass alphabetize (BMI), obesity, outcomes, risk factors
one. INTRODUCTION
In 2016, more than 1.ix billion adults worldwide were above healthy weight (trunk mass index [BMI] ≥ 25 kg/m2) and more than than 650 one thousand thousand of these individuals were living with obesity (BMI ≥ 30 kg/m2). 1 In line with this global tendency, the prevalence of obesity has risen steadily in the United kingdom, with a particularly sharp increase between 1993 and 2000. two A report past the System for Economical Co‐performance and Development using data from 2018 found that the UK overweight and obesity rates were some of the highest in Western Europe at 63% of the adult population 3 ; according to 2017 information, 26% of adults in England were living with obesity. iv
Beyond diverse observational studies, individuals with higher BMI were shown to exist at college gamble of a range of chronic atmospheric condition, including slumber apnea, 5 type 2 diabetes (T2D), gallbladder disease, and osteoarthritis, 6 compared with those of salubrious weight. In addition, higher BMI has been linked with college incidence of cardiovascular conditions such every bit hypertension, dyslipidemia, stroke, myocardial infarction (MI), and coronary center affliction.six, vii Cardiovascular affliction accounts for a considerable proportion of obesity‐related mortality: a meta‐analysis estimated that, in 2015, approximately 4 one thousand thousand deaths worldwide were attributable to high BMI, of which 2.7 million were linked to cardiovascular disease and 0.9 meg were linked to diabetes. eight Across studies, bloodshed has been shown to increase non‐linearly with increasing BMI.9, 10
The total toll to the UK National Health Service (NHS) of treating overweight, obesity and associated conditions was estimated at £6.1 billion in 2014–2015, and costs are projected to ascent to £9.seven billion by 2050. 11 Another projection of futurity obesity‐related healthcare costs in the United kingdom of great britain and northern ireland suggested that treatment of comorbid weather including T2D, center illness, and stroke is likely to institute a considerable proportion of this economic impact in the coming decades, with an estimated £ii billion annual excess spending on obesity‐related conditions by 2030. 12 Obesity and its comorbidities impose not just direct handling costs on healthcare systems, 13 just also indirect costs on society, such as loss of work productivity. fourteen
It is vital to assess further the association over fourth dimension between obesity and other wellness conditions, to understand both the clinical impact on individuals living with overweight or obesity and the wider brunt on healthcare systems. This study was designed to examine how a broad range of obesity‐related conditions and events associate with overweight or obesity, compared with healthy weight, in a large cohort considered generalizable to populations in everyday clinical practice. To let longitudinal cess of a large patient sample and inclusion of multiple relevant outcomes in the analyses, information from the well‐recognized Clinical Practice Enquiry Datalink (CPRD) GOLD were used. CPRD GOLD is a big, population‐representative UK primary care database that links to secondary care data sets and is widely used in epidemiology research beyond a broad range of disease areas, xv including obesity. 16
ii. MATERIALS AND METHODS
2.i. Data sources and written report population
This retrospective, longitudinal, observational cohort report used data from the CPRD GOLD, 17 an ongoing database of anonymized principal intendance records from full general practitioners in the United kingdom that includes information on patient demographics, disease symptoms, laboratory test results, diagnoses, handling, health‐related behaviors and referrals to secondary care. The individuals in CPRD GOLD are representative of the overall Uk adult population in terms of age, sex and ethnicity. 18
Information were extracted from the CPRD Golden database in Jan 2019 and merged with data from Hospital Episode Statistics and death registration information from the Office for National Statistics. This allowed information originating from hospital visits and fatal events that were not included in CPRD GOLD to be included in the analyses. Individuals included in this study were adults (aged 18 years or older) with at least one acme measurement and 1 weight measurement bachelor for calculating BMI during the index period (Jan 2000–Dec 2010) and registered in the database for at least three years before the engagement of BMI measurement (baseline BMI) inside the index period (Effigyone). If an individual had more than 1 BMI recorded during the index period, the earliest following iii years of enrollment in the database was taken as baseline BMI. Individuals included in the written report population were followed up for occurrence of relevant outcomes for a median of xi.4 years during the written report period (until January 2019; Effigy2 and Table1).
Study flow diagram. BMI, body mass index; CPRD, Clinical Practice Research Datalink
Study design. BMI, trunk mass alphabetize; MI, myocardial infarction; TIA, transient ischemic attack
TABLE 1
Baseline characteristics of the study population (n = two,924,952) by BMI group
| All individuals | BMI group, kg/m2 | |||||
|---|---|---|---|---|---|---|
| xviii.5–24.ix (reference grouping) | 25.0–29.9 Overweight | thirty.0–34.9 Obesity I | 35.0–39.9 Obesity II | 40.0–45.0 Obesity Three | ||
| Number of individuals | 2,924,952 | one,099,106 | i,074,953 | 507,425 | 176,237 | 67,231 |
| Sexual practice, number of women (%) | 1,672,338 (57.2) | 710,121 (64.6) | 534,496 (49.seven) | 269,204 (53.1) | 110,876 (62.ix) | 47,641 (70.9) |
| Smoking, number who e'er smoked (%) | one,455,484 (49.8) | 541,522 (49.3) | 539,516 (50.2) | 256,621 (fifty.6) | 86,026 (48.8) | 31,799 (47.3) |
| Median age, years (IQR) | 51 (37–64) | 47 (33–63) | 54 (40–66) | 52 (xl–64) | 49 (38–61) | 47 (37–58) |
| Median weight, kg (IQR) | 75.0 (64.4–87.0) | 63.0 (57.0–69.0) | 77.0 (70.0–85.0) | 90.0 (82.1–98.5) | 101.6 (93.4–111.6) | 114.iii (105.0–125.0) |
| Median follow‐upwardly, years (IQR) | xi.4 (half-dozen.8–14.viii) | 10.9 (5.viii–xiv.5) | 11.half dozen (7.4–xiv.9) | 11.seven (7.9–14.9) | 11.6 (7.9–xv.1) | 11.5 (7.8–14.nine) |
The study population was stratified into five groups based on baseline BMI. Individuals with a BMI of 18.5–24.9 kg/m2 were considered normal weight and used as the reference group in the data analyses. The other groups were BMI 25.0–29.9 kg/m2 (overweight), BMI thirty.0–34.nine kg/m2 (obesity I), BMI 35.0–39.9 kg/m2 (obesity II), and BMI 40.0–45.0 kg/m2 (obesity Three). Individuals with a BMI less than 18.v kg/mii were not included because they were considered to be outside the scope of a report studying the impact of overweight and obesity. Furthermore, variation in the underlying reasons for depression weight, such equally eating disorders or cancer, was considered to limit the validity of potential comparisons between this group and other BMI groups. A wider definition of obesity class III, used past the World Health Organization and the UK National Institute for Health and Care Excellence, includes all individuals with a BMI greater than 40 kg/g2.19, twenty In this report, the individuals with a BMI greater than 45.0 kg/m2 were more heterogeneous than the other BMI groups because there were a small-scale number of individuals with very high BMI and, therefore, may have skewed the risks and outcomes associated with this BMI group. This limited the validity of potential comparisons with the other BMI categories, each of which covered a 5‐point BMI range; consequently, individuals with a BMI greater than 45.0 kg/one thousand2 were excluded from the study.
2.2. Exposure and outcomes
The large number of health atmospheric condition known or suspected to be associated with obesity ways that the precise impact of obesity itself can be difficult to quantify fully. On the ground of a comprehensive report by the World Wellness Arrangement, which indicated that diseases across multiple organ systems are linked to obesity, 21 a broad range of atmospheric condition and events were selected for inclusion in analyses, which represent the cardiovascular, metabolic, endocrine, musculoskeletal, respiratory and renal systems.
For ease of reporting, the 12 obesity‐related conditions and events in the assay were grouped into five categories. The first category comprised the loftier‐prevalence weather T2D, hypertension and dyslipidemia. The 2nd category comprised other noncardiovascular conditions: asthma, sleep apnea, and osteoarthritis, whereas the 3rd category comprised cardiovascular–metabolic conditions (center failure, chronic kidney disease [CKD] and atrial fibrillation). The quaternary category was acute cardiovascular events, comprising two combined cardiovascular outcomes: unstable angina/MI and transient ischemic attack (TIA)/stroke. Finally, all‐cause mortality was captured by extracting expiry dates from CPRD Golden.
Conditions and events were identified past the presence of Read codes in CPRD Gilded and International Classification of Diseases, 10th revision codes in Hospital Episode Statistics and Role for National Statistics information (Tables S1 and S2), with the date of earliest diagnosis considered to be the outcome date (incident diagnosis). For hypertension and dyslipidemia, the event date was either the prescription date of anti‐hypertensive or lipid‐lowering medication, respectively, or the diagnosis date, whichever occurred first. The number of days from baseline to the diagnosis engagement was used as the fourth dimension to event. Follow‐upwards of each individual for a specific condition ended at the date of first relevant diagnosis, decease, transfer‐out date or written report stop (i January 2019), whichever occurred first.
Diagnoses that occurred before the start of follow‐upwards were as well captured in this study and were considered to institute baseline comorbidities. When generating the model for any given condition, individuals with the corresponding baseline comorbidity were excluded from the analysis. However, individuals with both baseline and incident diagnoses of acute cardiovascular events were eligible for inclusion in survival analyses, considering unstable angina/MI and TIA/stroke were modeled as potential recurring events rather than every bit i‐time chronic diagnoses.
two.3. Statistical analyses
Descriptive information for baseline characteristics were presented as median with interquartile range for continuous variables and every bit number and proportion (%) for chiselled variables. The prevalence of each comorbidity at baseline was calculated based on corresponding diagnoses or events recorded before the baseline date. These information were presented for the total cohort and for strata based on BMI group.
Cox proportional hazard models with age as the underlying timescale were used to judge the associations between BMI and each obesity‐related status or event. A separate model was developed for each condition/upshot and used to calculate the hazard ratio (Hr) and 95% conviction interval (CI) for each BMI group relative to the reference group. BMI was described every bit a chiselled variable, with the normal weight grouping (BMI xviii.5–24.9 kg/mii) as the reference category in the model. The analyses were adapted for sexual practice and smoking status, which were encoded as chiselled variables; smoking status was coded as either "always" or "never" based on whatsoever recorded smoking status before the baseline date.
In addition to the main analyses, supplementary analyses were carried out to appraise the bear upon of highly prevalent comorbidities (T2D, hypertension, and dyslipidemia) at baseline and any prevalent cardiovascular consequence (unstable angina, MI, TIA, or stroke) on the outcomes of interest. Cox proportional hazard models with age as the underlying timescale and adjusted for BMI group, sex activity, and smoking status were used, and the four comorbidities were encoded as categorical variables indicating presence/absence of the comorbidity at baseline. All statistical analyses were carried out using the R environment for statistical calculating and visualization (version 3.4.4).
two.4. Ethical blessing and use of data
The CPRD is a existent‐world research service supporting retrospective and prospective public health and clinical studies and is jointly sponsored by the Medicines and Healthcare Products Regulatory Agency and the National Institute for Health Research. The protocol for this study using secondary data was approved by the CPRD Independent Scientific Advisory Committee (protocol number 18_147), in accordance with the Declaration of Helsinki. Data were used in accordance with the terms agreed to upon their receipt. CPRD collects de‐identified patient information from a network of GP practices across the U.k., and this written report is therefore based on pseudonymized data from the CPRD.
iii. RESULTS
iii.1. Baseline characteristics
The study population included a full of 2,924,952 individuals. The median historic period of the study population at baseline was 51 years (interquartile range [IQR]: 37–64), and the median BMI was 26.5 kg/grandii (IQR: 23.5–30.1). In total, 57% of the study population were women. Individuals in the overweight and obesity I groups had a greater average age and a higher proportion of men than the total study population, whereas those in the normal weight, obesity Two and obesity III groups were younger on boilerplate and independent a higher proportion of women. Baseline characteristics and prevalence of comorbidities at baseline are shown in Table1 and Figure3, respectively.
Prevalence of comorbidities in the study population (north = 2,924,952) at baseline. Bars indicate split up BMI groups and labels prove prevalence in full study population. MI, myocardial infarction; TIA, transient ischemic assault
In the full study population, the virtually common baseline comorbidities were hypertension (present in 25.7% of the population), dyslipidemia (13.2%), asthma (xiii.1%), osteoarthritis (ten.1%), and T2D (five.ii%). Across all BMI groups, the prevalence of these five comorbidities was typically higher in individuals with higher BMI. All the same, unstable angina/MI, TIA/stroke and atrial fibrillation events had similar or lower prevalence at baseline in the obesity Two and obesity Three groups compared with lower BMI groups.
3.2. BMI and take chances of obesity‐related outcomes
Figure4 shows the gamble of (A) high‐prevalence atmospheric condition, (B) noncardiovascular conditions, (C) cardiovascular–metabolic weather, (D) cardiovascular events, and (E) all‐cause bloodshed for all BMI groups during the follow‐up period. Table S3 presents the corresponding HRs and 95% CIs.
Gamble of (A) high‐prevalence conditions, (B) noncardiovascular conditions, (C) cardiovascular–metabolic conditions, (D) cardiovascular events, and (E) all‐crusade mortality, past BMI grouping. Data shown are hazard ratios with 95% confidence intervals for each BMI group relative to the reference group (normal weight), derived from Cox proportional hazard models adjusted for historic period, sex, and smoking status. Note that y‐centrality scales differ between conditions. BMI, torso mass alphabetize; MI, myocardial infarction; TIA, transient ischemic attack
Compared with the reference group (18.five–24.9 kg/m2), the highest BMI group (40.0–45.0 kg/m2) had a higher hazard of all conditions and events. Individuals with a BMI of twoscore.0–45.0 kg/g2 were at particularly high risk of sleep apnea (Hour [95% CI]: nineteen.eight [18.9–20.8]) and T2D (12.4 [12.1–12.7]). These individuals besides had a more than threefold higher adventure of heart failure (iii.46 [three.35–3.57]) and hypertension (3.21 [3.15–3.26]) than individuals in the reference group. HRs for all other outcomes examined were in the range of one.2–2.8 for the BMI 40.0–45.0 kg/m2 group compared with the reference group.
In full general, at that place was a stepwise increment in adventure of high‐prevalence conditions, noncardiovascular atmospheric condition, cardiovascular–metabolic conditions and unstable angina/MI with increasing BMI grouping; however, individuals with a BMI of 25.0–29.9 kg/gtwo had a slightly lower adventure of TIA/stroke than those in the reference group (60 minutes [95% CI]: 0.96 [0.95–0.97]). This blueprint was also apparent in the analysis for all‐cause mortality, in both the BMI 25.0–29.ix kg/mii and the BMI xxx–34.ix kg/m2 groups (HRs [95% CIs]: 0.80 [0.79–0.81] and 0.88 [0.88–0.89], respectively).
Smoking was associated with a higher chance of all conditions and events studied, in particular unstable angina/MI (60 minutes [95% CI]: ane.54 [i.52–i.56]) and mortality (1.57 [one.56–i.58]). Male sex was a take a chance factor for all conditions and events with the exception of osteoarthritis (0.69 [0.68–0.69]), asthma (0.72 [0.71–0.73]), and CKD (0.91 [0.91–0.92]), which were more mutual in women (Table S3).
3.three. Contribution of baseline comorbidities to risk of obesity‐related outcomes
When the associations betwixt high‐prevalence baseline comorbidities, cardiovascular disease history and incident diagnoses occurring during the study period were examined, individuals with a previous diagnosis of T2D, hypertension, or dyslipidemia, or a history of cardiovascular events, were at higher risk of experiencing particular atmospheric condition than those without these baseline comorbidities (Effigyv and Table S4).
Risk of (A) high‐prevalence conditions, (B) noncardiovascular conditions, (C) cardiovascular–metabolic conditions, (D) cardiovascular events and (E) all‐cause bloodshed, by presence of loftier‐prevalence baseline comorbidities. Information shown are run a risk ratios with 95% confidence intervals for each high‐prevalence baseline comorbidity (type 2 diabetes, hypertension, dyslipidemia, and cardiovascular disease) relative to the absence of that comorbidity, derived from Cox proportional hazard models adapted for historic period, sex, smoking status, and presence of loftier‐prevalence baseline comorbidities. BMI, body mass index; CV, history of cardiovascular result(south); Dys, dyslipidemia; Hyp, hypertension; MI, myocardial infarction; T2D, blazon 2 diabetes; TIA, transient ischemic attack
T2D at baseline was associated with a more than threefold higher chance of being diagnosed with dyslipidemia (Hr [95% CI]: 3.12 [3.10–3.15]) and a more than doubled gamble of being diagnosed with hypertension (2.34 [2.32–two.37]). Individuals who had hypertension at baseline had nearly twice the risk of being diagnosed with CKD (1.93 [ane.92–ane.95]) or dyslipidemia (1.87 [1.86–1.88]), and also had an increased risk of T2D diagnosis (1.68 [1.67–one.70]), compared with those who were not diagnosed with hypertension before the start of the study menses. The baseline presence of dyslipidemia was associated with a comparatively higher hazard of a diagnosis of T2D (one.28 [1.26–1.30]), sleep apnea (one.26 [1.22–1.30]), or unstable angina/MI (1.26 [ane.25–one.28]) during the study period.
Individuals with a history of any cardiovascular effect had a more than twofold higher risk of experiencing an unstable angina/MI upshot (two.47 [2.43–2.51]), a dyslipidemia diagnosis (2.31 [2.28–2.33]), or a TIA/stroke event (2.17 [2.fourteen–2.xx]), and a nearly twofold higher take chances of center failure (1.91 [ane.88–1.94]) during the report flow, compared with those who had never experienced a cardiovascular event.
4. DISCUSSION
This study substantiates prove of a link between high BMI and 12 serious health atmospheric condition and events in a cohort of over ii.9 1000000 adults, representative of the United kingdom of great britain and northern ireland population. Individuals in the highest BMI group had a substantially college chance of all outcomes examined, with a 20‐times higher risk for sleep apnea, a 12‐times higher adventure for T2D, and a threefold college take chances of experiencing certain cardiovascular weather condition, compared with individuals of normal weight. The take chances for most conditions was generally greater in higher BMI groups, relative to groups with lower BMI. These findings are in line with previous studies showing a positive correlation between BMI and risk of these chronic weather and cardiovascular events.five, half dozen, 7 Individuals' sexual practice and smoking status affected the occurrence of health outcomes; furthermore, individuals with T2D, hypertension, or dyslipidemia at baseline had an increased gamble for developing another one of these three conditions in the future. There was as well an association betwixt baseline dyslipidemia or a history of cardiovascular events and the occurrence of these conditions during the written report period.
In this analysis, individuals in the overweight grouping had a higher risk of most outcomes than individuals in the reference group with healthy weight; however, this was not the instance for TIA/stroke and all‐cause mortality, for which individuals in the overweight and obesity I groups had a risk of experiencing these outcomes that was like to or lower than that for individuals with normal weight. These results for all‐cause bloodshed are in line with the findings of several previous meta‐analyses, which reported a J‐shaped distribution for bloodshed plotted against BMI.9, ten, 16, 22, 23, 24 Furthermore, an analysis of the Framingham Heart Study found lower bloodshed following ischemic stroke in individuals with BMI 25–xxx kg/mii compared with those who had normal weight. 25 A possible caption for the mortality findings is that illness can cause weight loss, leading to opposite causation bias: namely, conditions that comport an imminent risk of mortality can cause reductions in BMI, rather than BMI reductions causing mortality. This can lead to an underestimation of the mortality risks associated with overweight or obesity.ix, 26 To mitigate possible underestimation of mortality risks, a study design with long follow‐up was used, nine and adjustment were fabricated for known potential confounding factors including age, 23 sexual practice, 23 and smoking history.9, 24 However, residual confounding may still be nowadays.
In general, the prevalence of baseline comorbidities in the study accomplice increased with higher BMI, with the exceptions of unstable angina/MI, TIA/stroke, and atrial fibrillation, which had like or lower prevalence in the obesity Ii and obesity Three groups relative to other BMI groups. This may exist due to the disparities in median age and sex across the BMI groups, which resulted in a greater proportion of women and lower average age in the higher BMI groups than in the other groups. This pattern may be attributable to survival bias: older individuals with more severe obesity are probable to accept more cardiovascular comorbidities and consequently higher mortality; therefore, surviving individuals in these groups may have a disproportionately depression rate of certain comorbidities.
A major strength of this study is the utilization of a big, United kingdom of great britain and northern ireland‐representative primary care database, which allowed u.s.a. to examine a broad range of conditions in a single report population and to compare the relative magnitude of risks between outcomes. Furthermore, the large size of the report population, the long follow‐up menstruation, and the use of data from real‐world clinical practice mean that the results are robust and highly generalizable. Including individuals on the basis of a single eligible BMI measurement during the index flow greatly increased the available sample size, meaning that the analyses had strong statistical power to estimate the relationship between BMI and future illness hazard with a high degree of confidence. However, this study blueprint meant that BMI was not tracked over time, and therefore a more precise human relationship betwixt individual BMI changes and occurrence of obesity‐related weather condition cannot be inferred from the information.
Observational studies such as the present study can be field of study to misreckoning and other biases. Potential confounders, particularly details about individuals' lifestyles and certain demographic factors, such every bit ethnicity, are unlikely to be fully captured in primary care records and therefore are non taken into account in the analyses. Although diagnostic codes and prescriptions data are an adequate means of detecting disease incidence in such data sources, disparities in how certain conditions are detected, formally diagnosed and treated hateful that this method can lead to both over‐ and underpredictions of outcome risks. This tin likewise create bias when assessing associations between conditions; for example, the prescription of statins to treat dyslipidemia may increase T2D risk. 27 Finally, although BMI is a reliable screening tool for overweight and obesity, and is the best means of defining these conditions when using information sources in which simply summit and weight data are routinely collected, it should not exist used in isolation when other data are available. Waist circumference and body fat percentage are as well valuable indicators of obesity or obesity‐related risks and should be taken into consideration in clinical practice.28, 29, thirty
Some other limitation of the report was the requirement to exclude individuals with a BMI greater than 45 kg/mii; still, information technology is probable that interpretation of event risks for this group would take been skewed past a number of individuals with very loftier BMI. Additionally, the inclusion criterion requiring at least three years' registration in CPRD to capture adequate historical data meant that a large number of individuals were automatically excluded from the analysis, creating a potential for bias. Furthermore, in that location were differences between sample sizes in the study, which means that the big disparities in risks between the highest BMI group (northward = 67,231) and the reference group (n = one,099,106) should exist treated with a degree of circumspection. Information technology should besides be noted that individuals with higher BMI and/or more conditions of interest are disproportionately likely to take contact with primary care services, pregnant that comparatively fewer healthcare data are available for individuals of normal weight. Therefore, this study could feasibly have been biased toward detecting individuals with higher BMI. However, reporting of BMI in CPRD increased during the written report period, and from 2005 to 2011, 77% of included individuals had a previous BMI measurement, 31 which partly mitigates this adventure of bias.
The results of this study highlight the clear clan between BMI and the risk of futurity health outcomes and provide a valuable footing for farther research into obesity. Subsequent analyses are needed to quantify the contribution of other relevant risk factors, such as height, and, with modifications to our report design, the CPRD could also exist used to examine the impact of obesity on mental health in the aforementioned population. To show associations betwixt changes in BMI over time and obesity‐related complications, a dissimilar, longitudinal study design would be required; indeed, this has been carried out in a subsequent study using the CPRD.
Recent studies using the CPRD take besides highlighted the additional resource use incurred in populations who have T2D or cardiovascular disease in improver to obesity.32, 33 Although a sizable proportion of obesity‐related costs and resource use are known to be contributed by complications of the disease,34, 35 in that location is considerable variation in which conditions are included in overall cost estimation for obesity. 36 Therefore, also as demonstrating the cost benefits to be gained by a reduction in obesity rates, 37 data quantifying the affect of BMI on the run a risk of chronic conditions are needed to generate reliable inputs for economic evaluations of obesity.
Despite public health programs and management strategies, obesity prevalence remains loftier in many nations. 3 The clinical, societal, and economic impacts of obesity have been brought into sharper focus by the coronavirus illness 2019 (COVID‐19) pandemic. International information indicate that obesity is a risk gene for hospitalization and bloodshed associated with COVID‐19, 38 and preliminary studies in the UK populations have suggested that not merely is higher BMI positively correlated with COVID‐nineteen severity and bloodshed, merely other conditions that unremarkably occur as complications of obesity, such every bit T2D and hypertension, are besides risk factors for poor outcomes related to COVID‐xix.39, 40, 41 These findings take particularly severe implications in the United Kingdom, which both take some of the highest rates of overweight and obesity worldwide 3 and, at the time of writing, take one of the highest numbers of COVID‐19‐related deaths per million people. 42 Furthermore, equally the number of COVID‐19 cases increases, individuals with chronic wellness conditions are also probable to experience disruption to routine care due to increased pressure level on healthcare systems. 43 Every bit a consequence of the pandemic, public health and clinical strategies to reduce obesity rates have been appear every bit a major priority in the Great britain.44, 45 The results of the nowadays study illustrate how vitally this is needed for individuals, healthcare systems and society.
The results of this report bespeak that college BMI is associated with increased risks for a range of serious health weather condition. This demonstrates the requirement for effective treatments for individuals living with obesity, also as wider public wellness and health educational programs to slow and limit the development of the disease on a population level. 46 But via such measures can the considerable societal costs of obesity and its related atmospheric condition be mitigated, and its touch on healthcare systems 37 managed.
CONFLICTS OF INTEREST
Christiane 50. Haase, Kirsten T. Eriksen, Sandra Lopes, Altynai Satylganova and Volker Schnecke are employees of Novo Nordisk A/S. Altynai Satylganova and Sandra Lopes are likewise shareholders of Novo Nordisk A/S. Phil McEwan is an employee of Health Economics and Outcomes Research Ltd. Phil McEwan did not receive funding for this collaboration. HEOR Ltd have received funding from Novo Nordisk A/S for work conducted on previous studies.
Supporting information
ACKNOWLEDGMENTS
All authors contributed to study design, data interpretation, and writing and critical review of manuscript content. Christiane L. Haase, Kirsten T. Eriksen, Sandra Lopes, and Altynai Satylganova conducted literature searches, and Volker Schnecke performed data analysis. The authors acknowledge the medical writing help of Caroline Freeman of Oxford PharmaGenesis, Oxford, United Kingdom (funded by Novo Nordisk A/South).
REFERENCES
four. System for Economic Co‐performance and Evolution (OECD) . OECD Obesity Update. 2017. Accessed 25 September 2020. [Google Scholar]
5. Li C, Ford ES, Zhao K, Croft JB, Balluz LS, Mokdad AH. Prevalence of self‐reported clinically diagnosed sleep apnea according to obesity status in men and women: National Wellness and Nutrition Examination Survey, 2005‐2006. Prev Med. 2010;51:xviii‐23. [PubMed] [Google Scholar]
6. Must A, Spadano J, Coakley EH, Field AE, Colditz 1000, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523‐1529. [PubMed] [Google Scholar]
7. Khan SS, Ning H, Wilkins JT, et al. Association of body mass index with lifetime take chances of cardiovascular disease and pinch of morbidity. JAMA Cardiol. 2018;three:280‐287. [PMC free commodity] [PubMed] [Google Scholar]
8. G. B. D. Obesity Collaborators, Afshin A, Forouzanfar MH, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377:thirteen‐27. [PMC complimentary article] [PubMed] [Google Scholar]
9. Aune D, Sen A, Prasad M, et al. BMI and all‐cause mortality: systematic review and non‐linear dose‐response meta‐analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ. 2016;353:i2156. [PMC costless article] [PubMed] [Google Scholar]
10. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all‐cause mortality with overweight and obesity using standard trunk mass index categories: a systematic review and meta‐analysis. JAMA. 2013;309:71‐82. [PMC gratis commodity] [PubMed] [Google Scholar]
12. Wang YC, McPherson K, Marsh T, Gortmaker SL, Brown Chiliad. Health and economical burden of the projected obesity trends in the U.s. and the UK. Lancet. 2011;378:815‐825. [PubMed] [Google Scholar]
13. Counterweight Project Team . The impact of obesity on drug prescribing in main care. Br J Gen Pract. 2005;55:743‐749. [PMC free commodity] [PubMed] [Google Scholar]
xiv. Hoque ME, Mannan M, Long KZ, Al Mamun A. Economical burden of underweight and overweight among adults in the Asia‐Pacific region: a systematic review. Trop Med Int Health. 2016;21:458‐469. [PubMed] [Google Scholar]
sixteen. Bhaskaran Thou, Dos‐Santos‐Silva I, Leon DA, Douglas IJ, Smeeth 50. Association of BMI with overall and crusade‐specific mortality: a population‐based cohort written report of 3.6 million adults in the U.k.. Lancet Diabetes Endocrinol. 2018;6:944‐953. [PMC gratis article] [PubMed] [Google Scholar]
18. Herrett East, Gallagher AM, Bhaskaran K, et al. Data resource profile: clinical do research datalink (CPRD). Int J Epidemiol. 2015;44:827‐836. [PMC gratuitous article] [PubMed] [Google Scholar]
22. Global BMIMC, Di Angelantonio E, Bhupathiraju SN, et al. Trunk‐mass alphabetize and all‐crusade bloodshed: individual‐participant‐data meta‐analysis of 239 prospective studies in four continents. Lancet. 2016;388:776‐786. [PMC costless commodity] [PubMed] [Google Scholar]
23. Peter RS, Mayer B, Concin H, Nagel G. The effect of historic period on the shape of the BMI‐mortality relation and BMI associated with minimum all‐cause mortality in a large Austrian cohort. Int J Obes. 2015;39:530‐534. [PubMed] [Google Scholar]
24. Sunday YQ, Burgess Due south, Staley JR, et al. Torso mass index and all‐cause mortality in HUNT and UK Biobank studies: linear and non‐linear mendelian randomisation analyses. BMJ. 2019;364:l1042. [PMC free article] [PubMed] [Google Scholar]
25. Aparicio HJ, Himali JJ, Beiser Equally, et al. Overweight, obesity, and survival afterwards stroke in the Framingham heart study. J Am Centre Assoc. 2017;6:e004721. [PMC free article] [PubMed] [Google Scholar]
26. Yu East, Ley SH, Manson JE, et al. Weight history and all‐cause and crusade‐specific bloodshed in three prospective cohort studies. Ann Intern Med. 2017;166:613‐620. [PMC costless article] [PubMed] [Google Scholar]
27. Sattar N, Preiss D, Murray HM, et al. Statins and hazard of incident diabetes: a collaborative meta‐analysis of randomised statin trials. Lancet. 2010;375:735‐742. [PubMed] [Google Scholar]
28. Bouchard C. BMI, fat mass, abdominal adiposity and visceral fat: where is the 'beef'? Int J Obes. 2007;31:1552‐1553. [PubMed] [Google Scholar]
29. De Lorenzo A, Bianchi A, Maroni P, et al. Adiposity rather than BMI determines metabolic risk. Int J Cardiol. 2013;166:111‐117. [PubMed] [Google Scholar]
30. Rueda‐Clausen CF, Poddar Yard, Lear SA, Poirier P, Sharma AM. Canadian Adult Obesity Clinical Exercise Guidelines: Assessment of People Living with Obesity. Version i. 2020. https://obesitycanada.ca/guidelines/assessment. Accessed 29 October 2020. [Google Scholar]
31. Bhaskaran K, Forbes HJ, Douglas I, Leon DA, Smeeth L. Representativeness and optimal use of trunk mass index (BMI) in the UK Clinical Practice Enquiry Datalink (CPRD). BMJ Open. 2013;3:e003389. [PMC costless article] [PubMed] [Google Scholar]
32. le Roux CW, Chubb B, Nortoft E, Borglykke A. Obesity and healthcare resources utilization: results from clinical practise research database (CPRD). Obes Sci Pract. 2018;4:409‐416. [PMC costless article] [PubMed] [Google Scholar]
33. le Roux CW, Hartvig NV, Haase CL, Nordsborg RB, Olsen AH, Satylganova A. Obesity, cardiovascular risk and healthcare resource utilization in the UK. Eur J Prev Cardiol. 2020. 2047487320925639. [PubMed] [Google Scholar]
34. Kent S, Dark-green J, Reeves G, et al. Hospital costs in relation to body‐mass index in 1.1 one thousand thousand women in England: a prospective cohort written report. Lancet Public Health. 2017;2:e214‐e22. [PMC gratis article] [PubMed] [Google Scholar]
35. Kent Southward, Jebb SA, Greyness A, et al. Body mass index and use and costs of master care services among women aged 55‐79 years in England: a cohort and linked data report. Int J Obes. 2019;43:1839‐1848. [PMC free commodity] [PubMed] [Google Scholar]
36. Tremmel M, Gerdtham UG, Nilsson PM, Saha S. Economic burden of obesity: a systematic literature review. Int J Environ Res Publ Health. 2017;14. [PMC free article] [PubMed] [Google Scholar]
37. Cawley J, Meyerhoefer C, Biener A, Hammer Thou, Wintfeld Due north. Savings in medical expenditures associated with reductions in torso mass index among United states Adults with obesity, by diabetes status. Pharmacoeconomics. 2015;33:707‐722. [PMC free article] [PubMed] [Google Scholar]
38. Popkin BM, Du S, Light-green WD, et al. Individuals with obesity and COVID‐19: a global perspective on the epidemiology and biological relationships. Obes Rev. 2020;21. [PMC gratuitous article] [PubMed] [Google Scholar]
39. Docherty AB, Harrison EM, Greenish CA, et al. Features of 16,749 hospitalised UK patients with COVID‐19 using the ISARIC WHO clinical characterisation protocol. medRxiv. 2020. 10.1101/2020.04.23.20076042 [CrossRef] [Google Scholar]
40. Khawaja AP, Warwick AN, Hysi PG, et al. Associations with covid‐19 hospitalisation amongst 406,793 adults: the Uk Biobank prospective cohort written report. medRxiv. 2020. 10.1101/2020.05.06.20092957 [CrossRef] [Google Scholar]
41. Williamson E, Walker AJ, Bhaskaran KJ, et al. OpenSAFELY: factors associated with COVID‐19‐related hospital decease in the linked electronic health records of 17 million adult NHS patients. medRxiv. 2020. 10.1101/2020.05.06.20092999 [CrossRef] [Google Scholar]
42. World Health Arrangement . WHO coronavirus illness (COVID‐xix) dashboard. 2020. https://covid19.who.int/. Accessed 25 September 2020. [Google Scholar]
43. Chudasama YV, Gillies CL, Zaccardi F, et al. Bear on of COVID‐nineteen on routine care for chronic diseases: a global survey of views from healthcare professionals. Diabetes Metab Syndr. 2020;14:965‐967. [PMC free commodity] [PubMed] [Google Scholar]
44. Cuthbertson DJ, Alam U, Tahrani A. COVID‐xix and obesity: an opportunity for modify. Ther Adv Endocrinol Metab. 2020;eleven:2042018820949742. [PMC free article] [PubMed] [Google Scholar]
45. Mason L. Obesity in the age of COVID‐xix. Perspect Public Health. 2020;140:247‐248. [PubMed] [Google Scholar]
Manufactures from Obesity Science & Practice are provided here courtesy of Wiley-Blackwell
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019280/
0 Response to "Work Smart Witk Safe Work Again Jj White"
Post a Comment